EP2305805A1 — Double-stranded polynucleotide
Assigned to Daiichi Sankyo Co Ltd · Expires 2011-04-06 · 15y expired
What this patent protects
[Problem to be Solved] It is intended to provide a double-stranded polynucleotide that is resistant to RNase and has RNA interference effect, etc. [Solution] The present invention provides a double-stranded polynucleotide consisting of sense and antisense strand…
USPTO Abstract
[Problem to be Solved] It is intended to provide a double-stranded polynucleotide that is resistant to RNase and has RNA interference effect, etc. [Solution] The present invention provides a double-stranded polynucleotide consisting of sense and antisense strands consisting of polynucleotides comprising a nucleotide unit of DNAs and 2'-O-methyl RNAs alternately combined.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.